Research
Hormonal
Semaglutide improves NASH resolution in patients with stage 1-3 fibrosis but does not improve fibrosis or NASH resolution in patients with NASH-related cirrhosis.
Semaglutide can help resolve NASH in patients with early to moderate fibrosis, but it is not effective for reversing scarring in advanced cirrhosis, even if it helps with weight and metabolic markers.
GoodQualifiesHIGH confidence
Semaglutide, a GLP-1 RA, showed a significant dose-dependent NASH resolution without worsening of fibrosis in a phase 2 randomized controlled trial (RCT) involving patients with NASH and stage 1–3 fibrosis... However, in a recent phase 2 RCT for NASH-related cirrhosis, semaglutide did not improve fibrosis or NASH resolution
Why this rating
Based on phase 2 RCTs.
Source
Recent updates on pharmacologic therapy in non-alcoholic fatty liver disease
Young Woon Chang et al. · Clinical and Molecular Hepatology · 2023
DOI 10.3350/cmh.2023.0356
narrative_reviewCited 16×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Resmetirom, a liver-targeted thyroid hormone receptor beta agonist, significantly improves both NASH resolution and fibrosis in patients with stage 2-3 fibrosis.Good
- Obeticholic acid (OCA) reduces hepatic fibrosis without worsening NASH, but its efficacy is modest and it carries safety concerns leading to FDA rejection.Good
- Pegozafermin, an FGF21 analogue, significantly improves fibrosis and NASH resolution in patients with stage 2-3 fibrosis.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →